Patent classifications
C12N2710/14051
REMOVAL OF CONTAMINATING VIRUSES FROM AAV PREPARATIONS
The present invention relates to a separation of viruses of an essentially spherical shape from viruses with a rod-like shape that are comprised in a sample, wherein the sample comprising the viruses is subjected to filtration.
Production of virus occlusion bodies that occlude virions comprising genomes of different species of baculoviruses that can be used to combat insect pests
Production of virus occlusion bodies that occlude virions comprising genomes of different species of baculoviruses that can be used to combat insect pests. A method is presented for the production of occlusion derived virions (ODVs) that simultaneously comprise genomes of different baculovirus species, occluded in a viral occlusion body (OB) with the structural and morphological features characteristic of baculoviruses. Mixed genome ODVs and OBs can be produced by co-infecting insect cells or insect hosts using two or more different baculoviruses species. Co-infection may be achieved by simultaneous inoculation of the different baculoviruses or with a time interval between inoculations, which results in different proportions of each species' genomes in the ODVs and OBs that are produced. The produced OBs can be used either directly for preparing an insecticide, or to infect susceptible insects to produce larger quantities of mixed genome ODVs and OBs, also useful for combating pest insects.
MARKER SYSTEM, IN PARTICULAR FOR BACULOVIRUS-EXPRESSED SUBUNIT ANTIGENS
The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.
Removal of contaminating viruses from AAV preparations
The present invention relates to a separation of viruses of an essentially spherical shape from viruses with a rod-like shape that are comprised in a sample, wherein the sample comprising the viruses is subjected to filtration.
Marker system, in particular for baculovirus-expressed subunit antigens
The present invention belongs to the field of compliance markers and marker vaccines which allow for the differentiation between infected and vaccinated individuals. In particular, it relates to a method of determining whether an individual has received an immunogenic composition comprising a recombinant protein produced by a baculovirus expression system in cultured insect cells.
REMOVAL OF CONTAMINATING VIRUSES FROM AAV PREPARATIONS
The present invention relates to a separation of viruses of an essentially spherical shape from viruses with a rod-like shape that are comprised in a sample, wherein the sample comprising the viruses is subjected to filtration.
Method of viral production in cells
A method of using a cell to produce virus is provided involving growing cells under hyperosmotic conditions during a growth phase of the cells, infecting or transfecting the cells grown under hyperosmotic conditions with a virus, and maintaining the infected or transfected cells under less stressful conditions during a production phase of the infected or transfected cells to produce more of the virus. Viral productivity is improved by this method.
Baculovirus expression system
Method for preparing, in an insect cell, a recombinant baculovirus comprising one or more transgene(s) each encoding a protein maturation enzyme and n transgenes each encoding a polypeptide of interest, by homologous recombination between a replication deficient baculovirus genome which comprises one or more transgene(s) each encoding a protein maturation enzyme and n transfer vectors each comprising one of the n transgenes each encoding a polypeptide of interest, n being an integer at least equal to 2.
Production of Lentiviral Vectors
A high-volume gene therapy vector manufacturing process which produces a recombinant gene therapy vector which is able to transform host cells even when they are not dividing.
PROTEIN-BASED NANOPARTICLE FOR SELF-PACKAGING AND DELIVERING MRNA, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION
A method for preparing protein-based nanoparticle for self-packaging and delivering mRNA includes the following steps. A first donor plasmid, a second donor plasmid and a third donor plasmid are provided. A plasmid transposing step is performed. A recombinant virus preparing step is performed so as to obtain a first recombinant baculovirus, a second recombinant baculovirus and a third recombinant baculovirus. A transducing step is performed, wherein the first recombinant baculovirus, the second recombinant baculovirus and the third recombinant baculovirus are used to infect a producer cell so as to express a nucleocapsid protein, an envelope protein, an engineered envelope protein and a target RNA, and the nucleocapsid protein, the envelope protein, the engineered envelope protein and the target RNA are self-assembled to form a protein-based nanoparticle for self-packaging and delivering mRNA.